Daniel Muehl
Director/Board Member bei Clovis Oncology UK Ltd.
Profil
Daniel W.
Muehl is currently a Director at Clovis Oncology UK Ltd.
He previously worked as a Chief Financial Officer at Repligen Corp., International Precious Minerals Group, Inc., and Physiometrix, Inc. He also worked as a Vice President-Finance at Pharmion Corp.
and as a Chief Financial Officer at OPX Biotechnologies, Inc. and SomaLogic Operating Co., Inc. Additionally, he worked as a Principal at Ernst & Young LLP and Horwath Velez & Co. PSC.
He received his undergraduate degree from the University of Massachusetts.
Aktive Positionen von Daniel Muehl
| Unternehmen | Position | Beginn |
|---|---|---|
Clovis Oncology UK Ltd.
 Clovis Oncology UK Ltd. BiotechnologyHealth Technology Part of Clovis Oncology, Inc., Clovis Oncology UK Ltd. is a private company that engages in research and development on biotechnology. Clovis Oncology UK Ltd. is based in Cambridge, UK. | Director/Board Member | - |
Ehemalige bekannte Positionen von Daniel Muehl
| Unternehmen | Position | Ende |
|---|---|---|
| CLOVIS ONCOLOGY, INC. | Director of Finance/CFO | 10.07.2023 |
SomaLogic Operating Co., Inc.
 SomaLogic Operating Co., Inc. Medical SpecialtiesHealth Technology SomaLogic Operating Co., Inc. engages in the development of technologies used in the areas of diagnostics, clinical research, and pharmaceutical development. It offers protein biomarker systems for applications in drug discovery, therapeutic treatments, and wellness monitoring. The firm's products and services include SOMAscan service, SOMAscan at the institution, individual SOMAscan reagents, SOMAmer discovery service, SomaLogic CLIA laboratory, and technical support. The company was founded by Larry Gold and David Brunel in 2000 and is headquartered in Boulder, CO. | Director of Finance/CFO | 01.06.2015 |
| STANDARD BIOTOOLS INC. | Director of Finance/CFO | 01.01.2015 |
OPX Biotechnologies, Inc.
 OPX Biotechnologies, Inc. BiotechnologyHealth Technology OPX Biotechnologies, Inc. engages in the development and production of bio-based chemicals and fuels. The company was founded by Ryan T. Gill, Peter Long, and Michael Lynch in 2007 and is headquartered in Boulder, CO. | Director of Finance/CFO | 01.04.2014 |
| REPLIGEN CORPORATION | Director of Finance/CFO | 01.09.2007 |
Ausbildung von Daniel Muehl
| University of Massachusetts | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| REPLIGEN CORPORATION | Health Technology |
| INTERNATI | Non-Energy Minerals |
| STANDARD BIOTOOLS INC. | Commercial Services |
| Private Unternehmen | 8 |
|---|---|
Physiometrix, Inc.
 Physiometrix, Inc. Medical SpecialtiesHealth Technology Physiometrix, Inc. used to manufacture equipment for general anesthesia and surgical procedures. The company was engaged in designing, development, manufacturing and marketing of noninvasive, advanced medical products, incorporated electronics technology and software for use in neurological monitoring applications during surgical and diagnostic procedures. The company was located in North Billerica, MA. | Health Technology |
Ernst & Young LLP
 Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY. | Commercial Services |
OPX Biotechnologies, Inc.
OPX Biotechnologies, Inc. BiotechnologyHealth Technology OPX Biotechnologies, Inc. engages in the development and production of bio-based chemicals and fuels. The company was founded by Ryan T. Gill, Peter Long, and Michael Lynch in 2007 and is headquartered in Boulder, CO. | Health Technology |
Horwath Velez & Co. PSC
 Horwath Velez & Co. PSC Miscellaneous Commercial ServicesCommercial Services Horwath Velez & Co. PSC is a private company based in Washington. | Commercial Services |
SomaLogic Operating Co., Inc.
SomaLogic Operating Co., Inc. Medical SpecialtiesHealth Technology SomaLogic Operating Co., Inc. engages in the development of technologies used in the areas of diagnostics, clinical research, and pharmaceutical development. It offers protein biomarker systems for applications in drug discovery, therapeutic treatments, and wellness monitoring. The firm's products and services include SOMAscan service, SOMAscan at the institution, individual SOMAscan reagents, SOMAmer discovery service, SomaLogic CLIA laboratory, and technical support. The company was founded by Larry Gold and David Brunel in 2000 and is headquartered in Boulder, CO. | Health Technology |
Pharmion Corp.
 Pharmion Corp. Pharmaceuticals: MajorHealth Technology Pharmion Corp. engages in the development and commercialization of products for the treatment of hematology and oncology patients. It has operations in Switzerland, Israel, and Philippines. The company was founded by Patrick J. Mahaffy in 1999 and is headquartered in Boulder, CO. | Health Technology |
Clovis Oncology, Inc.
 Clovis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. Its U.S. marketed product, Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is approved for use in the maintenance treatment and treatment of eligible adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer, and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC), which have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. In Europe, Rubraca is approved for use in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO. | Health Technology |
Clovis Oncology UK Ltd.
Clovis Oncology UK Ltd. BiotechnologyHealth Technology Part of Clovis Oncology, Inc., Clovis Oncology UK Ltd. is a private company that engages in research and development on biotechnology. Clovis Oncology UK Ltd. is based in Cambridge, UK. | Health Technology |
